These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-000213-19 Sertindole versus risperidone safety outcome study: A randomised, partially-blinded, parallel-group, active-controlled, post-marketing study 2008-01-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2004-000320-32 A double-blind, randomised, multicenter, fixed-dose study comparing the efficacy of escitalopram (20mg/day) with that of citalopram (40mg/day) in patients with major depressive disorder 2010-04-16 bad-data
Completed, but no date, and reported results 2004-000707-18 A 40-week open, flexible dose, extension study of bifeprunox in patients with schizophrenia. bad-data
Reported results 2004-000990-78 A Double-Blind, Multicentre, Randomised, Parallel-group, Placebo-controlled Study Assessing the Efficacy and Safety of Escitalopram in Post-Myocardial Infarction Patients Suffering from Depressive Sym... 2005-06-03 due-trials
Completed, but no date, and reported results 2004-001264-45 Protocol title study No. 10402: A 12-month Phase III safety study of gaboxadol 10 mg daily consisting of a 6-month double-blind, randomised, placebo-controlled, parallel-group periodfollowed by a 6-... bad-data
Completed, but no date, and reported results 2004-001265-18 Protocol title No.10403: A double-blind, randomised, placebo-controlled, parallel-group, Phase III study evaluating the efficacy and safety of gaboxadol 5 mg and 10 mg daily in elderly outpatients wit... bad-data
Ongoing, reported early 2004-002185-38 A 6 months double-blind, risperidone-referenced, flexible dose, parallel-group extension study of bifeprunox in patients with schizophrenia not-yet-due
Ongoing 2004-002591-42 A pharmacoeconomic study conducted in parallel with clinical trial 10200, a 24-week double-blind, risperidone-referenced, flexible dose, parallel-group extension study of bifeprunox in patients with s... not-yet-due
Listed as ongoing, but also has a completion date and reported results 2004-002614-10 A 1-Year Randomised, Double-Blind Placebo-Controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients with Alzheimer’s Disease 2009-02-12 bad-data
Listed as ongoing, but also has a completion date and reported results 2004-005069-39 A double-blind, randomised, multicenter, comparative study of escitalopram and duloxetine in outpatients with Major Depressive Disorder 2006-11-10 bad-data
Reported results 2005-000497-50 An open-label safety study of bifeprunox investigating flexible doses of 20, 30, or 40mg/day in patients with schizophrenia who have completed studies 10206 or 10265 2008-07-21 due-trials
Listed as ongoing, but also has a completion date and reported results 2005-002038-36 A randomised, double-blind, placebo-controlled, 6-month study of the efficacy and safety of memantine in patients with Parkinson s disease dementia or dementia with Lewy Bodies 2009-01-29 bad-data
Not reported 2005-005499-34 A double-blind, randomised, placebo-controlled, quetiapine-referenced, multicentre study of the long-term bifeprunox efficacy, safety and tolerability in patiens with stable schizophrenia 2007-05-04 due-trials
Listed as ongoing, but also has a completion date 2006-000860-10 An Open-Label Study Investigating the Specific Effects of Memantine in Institutionalised Patients with Alzheimer’s Disease 2006-09-04 bad-data
Reported results 2006-001515-29 Double-blind, randomised, placebo-controlled study comparing the efficacy and safety of two fixed dosages of a novel antidepressant compound to that of placebo in patients with Major Depressive Disor... 2008-10-03 due-trials
Reported results 2006-003739-57 A double-blind, randomised, parallel-group, placebo-controlled study investigating the safety- and tolerability following fixed oral dose regimens (daily versus twice weekly administration) of Lu 31-1... 2009-11-06 due-trials
Completed, reported early 2006-004530-33 Rasagiliinin ja essitalopraamin yhteiskäytön turvallisuus 2016-08-23 not-yet-due
Reported results 2007-000905-31 A long term open label, flexiable dose, extension study evaluationg the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder 2008-10-07 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-001071-11 Randomised, double-blind, parallel-group, placebo-controlled, duloxetine referenced, dose-finding study of Lu AA24530 in Major Depressive Disorder 2009-03-13 bad-data
Reported results 2007-001097-90 A one-year multinational, multi-centre, randomised, double-blind, parallel-group, fixed-dose, bifeprunox study combining a 12 week placebo-controlled, quetiapine-referenced phase with a 12-month queti... 2009-06-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-001870-95 A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosages of Lu AA21004, in acute treatment of Major D... 2009-04-02 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-001871-13 A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with two doses of Lu AA21004 in patients with Major Depressive Disorder. 2009-09-07 bad-data
Ongoing, reported early 2007-002160-10 A prospective, open-label, single arm, multinational, multi-centre, flexible dose, extension study of the SCoP 99824 with sertindole for patients suffering from schizophrenia not-yet-due
Reported results 2007-002315-92 A 52-week, randomised, double-blind, placebo-controlled, parallel-group, safety and tolerability study of nalmefene, as needed use, in patients with alcohol dependence 2010-11-03 due-trials
Reported results 2007-002334-11 Nalmefene Efficacy Study I: Randomised, double-blind, placebo-controlled, parallel-group, efficacy study of 20 mg nalmefene, as needed use, in patients with alcohol dependence 2010-10-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-002551-17 Randomised, double-blind, parallel-group, placebo-controlled, and active referenced study of Lu AA34893 to evaluate the efficacy and safety of three doses Lu AA34893 and quetiapine versus placebo in t... 2009-10-30 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-002563-27 Estudio II de eficacia de Nalmefene: Estudio de eficacia aleatorizado, doble ciego, controlado por placebo, de grupo paralelo, con 20 mg de nalmefene, según se necesite, en pacientes con dependencia d... 2011-03-22 bad-data
Completed, but no date, and reported results 2007-004009-93 Prevalence of depression,anxiety and impulse control disorder (ICD) in patients with Parkinson's disease and effectiveness of escitalopram bad-data
Reported results 2007-004322-24 Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Clobazam (0.25, 0.5 and 1.0 mg/kg/day) in Patients with Lennox-Gastaut Syndrome. 2010-04-23 due-trials
Reported results 2007-004350-82 Safety and Effectiveness of Open-Label Clobazam in Subjects with Lennox Gastaut Syndrome 2012-09-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-004992-21 A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 in patients with Major Depressive Disorder 2010-03-23 bad-data
Listed as ongoing, but also has a completion date and reported results 2007-007025-51 A randomised, double-blind, parallel-group, placebo-controlled and active-referenced study evaluating the efficacy and safety of three fixed dose regimens of Lu AA34893 in the treatment of Major Depre... 2009-04-14 bad-data
Ongoing, reported early 2008-000479-11 A randomised, double-blind, parallel-group, active-controlled, flexible dose study exploring the efficacy and safety of 12 weeks treatment with Lu 31-130 in patients with schizophrenia not-yet-due
Reported results 2008-000506-36 Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose comparison study of escitalopram in combination with two fixed doses of gaboxadol to escitalopram in Major Depressive Disorder 2009-12-18 due-trials
Listed as ongoing, but also has a completion date and reported results 2008-000622-40 A randomised, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke. 2014-07-07 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001441-26 A randomised, double-blind, parallel-group, fixed dose study exploring the efficacy and safety of Lu AE58054 as augmentation therapy to risperidone in patients with schizophrenia. 2010-01-15 bad-data
Listed as ongoing, but also has a completion date and reported results 2008-001673-15 A double-blind, randomised, placebo-controlled, multicentre, relapse-prevention study with Lu AA21004 in patients with Generalised Anxiety Disorder (GAD) 2010-06-14 bad-data
Completed, but no date, and reported results 2008-002164-34 Randomised, double-blind, 3-way crossover, single dose, placebo-controlled study investigating the effect on postural instability of melatonin and zolpidem in healthy elderly subjects bad-data
Listed as ongoing, but also has a completion date and reported results 2008-002901-38 Randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed dose study comparing the efficacy and safety of Lu AA21004 in acute treatment of major depressive disorder in... 2010-02-03 bad-data
Reported results 2008-003662-25 Randomised, double blind, placebo controlled study of Lu AA24493 in patients with Friedreich's Ataxia to evaluate safety and tolerability and to explore efficacy 2011-03-11 due-trials
Other 2008-005353-38 Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 7 to 11 years, with Major depressive disorder ... not-yet-due
Other 2008-005354-20 Interventional, randomised, double-blind, placebo-controlled, active reference (fluoxetine), fixed-dose study of vortioxetine in paediatric patients aged 12 to 17 years, with Major depressive disorder... not-yet-due
Other 2008-005356-25 Long-term, open-label, flexible-dose, extension study of vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 18 years of age not-yet-due
Listed as ongoing, but also has a completion date and reported results 2008-005539-14 A randomised, double-blind, parallel-group, placebo-controlled phase III study to evaluate the efficacy and safety of desmoteplase in subjects with acute ischemic stroke. 2014-10-07 bad-data
Completed, but no date, and reported results 2009-011144-19 A randomised, double-blind, placebo-controlled study to evaluate if rasagiline can improve depressive symptoms and cognitive function in non-demented, idiopathic Parkinson s disease patients. bad-data
Listed as ongoing, but also has a completion date and reported results 2009-011845-24 Estudio aleatorizado, doble ciego, de grupos paralelos, controlado con placebo, de Lu AE58054 a dosis fijas en pacientes con enfermedad de Alzheimer moderada tratados con donepezilo 2011-12-23 bad-data
Reported results 2009-017523-26 A randomised, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of Lu AA21004 (15 and 20 mg/day) in the acute treatment of ad... 2011-12-12 due-trials
Reported results 2010-020170-42 An open-label study evaluating the Pharmacokinetics and Tolerability of Lu AA21004 in connection with multiple oral dosing of Lu AA21004 in child and adolescent patients with a DSM-IV-TRTM diagnosis o... 2014-12-10 due-trials
Reported results 2010-022181-28 A 6-month, randomised, double-blind, parallel-group, risperidone-controlled, fixed-dose study evaluating the safety and efficacy of zicronapine in patients with schizophrenia 2012-10-09 due-trials
Reported results 2010-024198-38 A long-term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu AA21004 (15 and 20 mg/day) in patients with Major Depressive Disorder 2012-09-28 due-trials
Reported results 2011-001572-19 Randomised, double-blind, parallel-group, placebo-controlled, fixed dose study on the efficacy of Lu AA21004 on cognitive dysfunction in adult patients with Major Depressive Disorder (MDD) 2013-05-20 due-trials
Ongoing, reported early 2011-001839-23 Interventional randomised, double-blind, parallel-group, not-yet-due
Reported results 2011-002362-21 A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder wi... 2012-12-20 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-001361-32 Interventional, randomised, double-blind, parallel-group, 2014-05-22 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-001380-76 Interventional, randomised, double-blind, parallel-group, 2016-06-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-002252-17 Interventional, randomised, double-blind, parallel-group, placebo-controlled, active-reference, flexible-dose study of brexpiprazole in patients with acute schizophrenia 2014-12-17 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-002705-21 Interventional, open-label, flexible-dose extension study of 2015-12-30 bad-data
Reported results 2012-002785-12 A 28-week, randomised, open-label study evaluating the effectiveness of aripiprazole once-monthly versus paliperidone palmitate in adult patients with 2015-01-16 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-003239-47 Interventional, open-label, flexible-dose extension study of aripiprazole once-monthly in patients with schizophrenia 2015-07-01 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-004169-42 Interventional, open-label, long-term extension study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in patients with major depressive disorder. 2014-04-01 bad-data
Reported results 2012-004763-45 Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil 2016-07-19 due-trials
Listed as ongoing, but also has a completion date and reported results 2012-004764-22 Randomised, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer’s disease treated with donepezil; Study 2 2017-07-08 bad-data
Listed as ongoing, but also has a completion date and reported results 2012-004765-40 Randomised, double-blind, parallel-group, placebo-controlled 2017-01-12 bad-data
Reported results 2012-004982-41 Interventional, randomised, double-blind, parallel-group, 2015-10-30 due-trials
Listed as ongoing, but also has a completion date and reported results 2013-000001-23 An open-label extension study to evaluate the long-term safety and tolerability of Lu AE58054 as adjunctive treatment to donepezil in patients with mild-moderate Alzheimer's disease 2017-07-06 bad-data
Reported results 2013-001154-98 Interventional, randomized, double-blind, cross-over, placebo-controlled study to investigate the effects of nalmefene after single dose on the blood oxygen level dependent (BOLD) fMRI signal in the v... 2014-10-30 due-trials
Reported results 2013-004688-30 Interventional, open-label study of 18 mg Selincro® as needed use, in the treatment of patients with alcohol dependence in primary care 2016-02-23 due-trials
Reported results 2014-000229-19 An interventional, randomised, double-blind, parallel-group, placebo-controlled study on the efficacy of vortioxetine on cognitive dysfunction in patients with partial or full remission of major depre... 2016-04-25 due-trials
Reported results 2014-000230-34 An interventional, randomised, double-blind, parallel-group, placebo-controlled, active-referenced (paroxetine), fixed-dose study on the efficacy of vortioxetine on cognitive dysfunction in working pa... 2016-02-05 due-trials
Reported results 2014-000231-16 An interventional, randomised, double-blind, parallel-group, 2016-03-01 due-trials
Reported results 2014-000413-31 Exploratory, interventional, open-label, fixed-dose study with Selincro® as-needed use, in alcohol dependent patients with liver impairment 2015-12-04 due-trials
Reported results 2014-003547-35 Interventional, open-label, flexible-dose, long-term study to evaluate the safety and tolerability of brexpiprazole as adjunctive treatment in elderly patients with major depressive disorder with an i... 2016-06-01 due-trials
Listed as ongoing, but also has a completion date 2014-003569-12 Interventional, randomised, double-blind, active-controlled, 2018-10-08 bad-data
Other 2015-002658-11 Long-term, open-label, flexible-dose, continuation extension study with vortioxetine in child and adolescent patients with Major Depressive Disorder (MDD) from 7 to 17 years of age not-yet-due
Ongoing 2015-003284-11 Interventional, open-label, flexible-dose, long-term safety study of Lu AF35700 in adult patients with schizophrenia not-yet-due
Reported results 2015-005081-30 Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients w... 2017-04-27 due-trials
Ongoing 2017-000788-34 Interventional, randomized, double-blind, active-controlled study of the efficacy of Lu AF35700 in patients with early-in-disease or late-in-disease treatment-resistant schizophrenia not-yet-due
Ongoing 2018-000992-34 Interventional, randomized, double-blind, placebo-controlled not-yet-due